Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients

Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients ORIGINAL CONTRIBUTION Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients M. Alan Brookhart, PhD Context Controversy exists about optimal management of anemia in end-stage re- Sebastian Schneeweiss, MD, ScD nal disease. Jerry Avorn, MD Objective To compare the mortality risk of different dialysis center–level patterns of anemia management. Brian D. Bradbury, DSc Design, Setting, and Patients Using data from Medicare’s end-stage renal dis- Jun Liu, MD ease program (1999-2007), we characterized each US dialysis center’s annual anemia Wolfgang C. Winkelmayer, MD, ScD management practice by estimating its typical use of erythropoiesis-stimulating agents (ESAs) and intravenous iron in hemodialysis patients within 4 hematocrit categories. PPROPRIATE USE OF ERYTHRO- We used Cox proportional hazards regression to correlate center-level patterns of ESA poiesis-stimulating agents and iron use with 1-year mortality risk in 269 717 incident hemodialysis patients. (ESAs) and intravenous iron Main Outcome Measure One-year all-cause mortality. Acan effectively manage the Results Monthly mortality rates were highest in patients with hematocrit less than 30% anemia of chronic kidney disease and (mortality, 2.1%) and lowest for those with hematocrit of 36% or higher (mortality, 0.7%). 1-3 end-stage renal disease (ESRD), but After adjustment for baseline case-mix differences, dialysis centers that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients

Loading next page...
 
/lp/american-medical-association/comparative-mortality-risk-of-anemia-management-practices-in-incident-QRb3oK05YV

References (57)

Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2010.206
pmid
20197532
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients M. Alan Brookhart, PhD Context Controversy exists about optimal management of anemia in end-stage re- Sebastian Schneeweiss, MD, ScD nal disease. Jerry Avorn, MD Objective To compare the mortality risk of different dialysis center–level patterns of anemia management. Brian D. Bradbury, DSc Design, Setting, and Patients Using data from Medicare’s end-stage renal dis- Jun Liu, MD ease program (1999-2007), we characterized each US dialysis center’s annual anemia Wolfgang C. Winkelmayer, MD, ScD management practice by estimating its typical use of erythropoiesis-stimulating agents (ESAs) and intravenous iron in hemodialysis patients within 4 hematocrit categories. PPROPRIATE USE OF ERYTHRO- We used Cox proportional hazards regression to correlate center-level patterns of ESA poiesis-stimulating agents and iron use with 1-year mortality risk in 269 717 incident hemodialysis patients. (ESAs) and intravenous iron Main Outcome Measure One-year all-cause mortality. Acan effectively manage the Results Monthly mortality rates were highest in patients with hematocrit less than 30% anemia of chronic kidney disease and (mortality, 2.1%) and lowest for those with hematocrit of 36% or higher (mortality, 0.7%). 1-3 end-stage renal disease (ESRD), but After adjustment for baseline case-mix differences, dialysis centers that

Journal

JAMAAmerican Medical Association

Published: Mar 3, 2010

There are no references for this article.